Over the past 5 years, the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) has continued its upward trajectory in cancer research excellence and service to its catchment area. The WFBCCC catchment area includes the Piedmont and southern Appalachia, a region of 58 contiguous counties in North Carolina, Virginia, West Virginia and Tennessee. The majority of this region is rural and exhibits significant racial health disparities. Elevated age-adjusted smoking rates, obesity rates, cancer incidence, and cancer mortality are observed across the WFBCCC catchment area when compared with the rest of the U.S. To target these issues, the WFBCCC conducts cutting-edge basic, clinical, and population research on the prevention, detection and treatment of cancer, and translates this knowledge into strategies to improve patient outcomes and reduce the incidence of cancer. WFBCCC cancer research funding is $37.9 million, of which over $14.9 million comes from the NCI; this represents a 25.3% increase in total cancer funding since the last CCSG renewal. Center research space under the Director?s authority increased by approximately 65,000 square feet, and the WFBCCC clinical facilities have been dramatically enhanced with the completion of the new eleven- story Cancer Hospital in 2013. This building houses all oncology inpatients and outpatients. The Center?s 127 members span the basic, clinical and population sciences and are organized into 4 Programs with substantial inter-and intra-programmatic productivity. Faculty additions enhanced tobacco control, tobacco-related cancer research, and precision medicine. Substantial investment in faculty, technology, and informatics significantly expanded cancer genomics capabilities. Enrollment of patients into treatment trials reached an all-time high in 2015, with a large increase in the number of patients enrolled in investigator-initiated trials. WFBCCC population scientists initiated exciting new efforts in cancer prevention and survivorship. Clinical scientists completed practice-changing studies in patients with glioma and lung cancer. Groundbreaking observations in prostate cancer emerged from WFBCCC inter-programmatic collaborations. WFBCCC basic science Programs continued to make high impact observations that are being translated into human therapeutics. The WFBCCC requests continued CCSG funding for 4 scientific Programs; 7 Shared Resources; 2 clinical research components; administration and leadership; planning and evaluation; and developmental funds. With these funds, a talented faculty integrated throughout the Cancer Center will make advances in the prevention, early detection, and treatment of cancer in the WFBCCC catchment area and the nation.
The Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) is a matrix Cancer Center, which serves the people of the multistate Piedmont and southern Appalachian region. The WFBCCC is the hub for clinical, basic, and population researchers focused on the prevention and early detection of cancer, developing novel cancer therapy, and improving the health of cancer survivors. WFBCCC is integral to the research mission of the Wake Forest Baptist Medical Center (WFBMC) in Winston-Salem, North Carolina, and is one of its largest research components. The WFBCCC unites the cancer research capabilities of multiple institutional units including the WFBMC, Wake Forest University and the Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences. The WFBCCC serves a broad educational mission for Wake Forest University students and faculty as well as for practitioners and caregivers across the region. The WFBCCC strives to reduce cancer incidence, morbidity and mortality regionally, nationally, and internationally through cutting-edge research and treatments, education and outreach, and multi- disciplinary training.
|Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162|
|Haas, Karen M; Johnson, Kristen L; Phipps, James P et al. (2018) CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens. J Immunol 200:1671-1681|
|Suo, Xubin; Eldridge, Brittany N; Zhang, Han et al. (2018) P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes. ACS Appl Mater Interfaces 10:33464-33473|
|Widner, D Brooke; Park, Sun H; Eber, Matthew R et al. (2018) Interactions Between Disseminated Tumor Cells and Bone Marrow Stromal Cells Regulate Tumor Dormancy. Curr Osteoporos Rep 16:596-602|
|Liu, Liang; Ruiz, Jimmy; O'Neill, Stacey S et al. (2018) Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer 17:81|
|Sirkisoon, Sherona R; Carpenter, Richard L; Rimkus, Tadas et al. (2018) Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene 37:2502-2514|
|Goyal, Amrita; Carter, Joi B; Pashtan, Itai et al. (2018) Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study. J Am Acad Dermatol 78:408-410|
|Su, Weijun; Hong, Lixin; Xu, Xin et al. (2018) miR-30 disrupts senescence and promotes cancer by targeting both p16INK4A and DNA damage pathways. Oncogene 37:5618-5632|
|Miller Jr, David P; Denizard-Thompson, Nancy; Weaver, Kathryn E et al. (2018) Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial. Ann Intern Med 168:550-557|
|Rimkus, Tadas K; Carpenter, Richard L; Sirkisoon, Sherona et al. (2018) Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer Res 78:2589-2600|
Showing the most recent 10 out of 548 publications